Menlo Therapeutics Inc. Uncategorized Contracts & Agreements
23 Contracts & Agreements
- Letter Agreement, dated as of February 27, 2023, by and between VYNE Therapeutics Inc. and Tay Therapeutics Ltd (Filed With SEC on May 11, 2023)
- Description of Securities Registered Under Section 12 of the Securities Exchange Act of 1934 (Filed With SEC on March 14, 2023)
- Letter Agreement, dated as of June 15, 2022, by and between VYNE Therapeutics Inc. and In4Derm Limited (Filed With SEC on August 12, 2022)
- Offer Letter, dated as of March 15, 2022, by and between VYNE Pharmaceuticals Inc. and Tyler Zeronda (Filed With SEC on March 17, 2022)
- Offer Letter, dated as of March 7, 2022, by and between VYNE Pharmaceuticals Inc. and Iain Stuart (Filed With SEC on March 17, 2022)
- Description of Securities Registered Under Section 12 of the Securities Exchange Act of 1934 (Filed With SEC on March 17, 2022)
- Evaluation and Option Agreement, dated as of April 30, 2021, by and between In4Derm Limited and VYNE Therapeutics Inc (Filed With SEC on November 10, 2021)
- Offer Letter, dated as of June 7, 2021, by and between Tyler Zeronda and VYNE Pharmaceuticals Inc (Filed With SEC on August 12, 2021)
- Offer Letter, dated as of April 7, 2021, by and between Mutya Harsch and VYNE Pharmaceuticals Inc (Filed With SEC on May 6, 2021)
- Offer Letter, dated as of April 7, 2021, by and between Andrew Saik and VYNE Pharmaceuticals Inc (Filed With SEC on May 6, 2021)
- Description of Securities Registered Under Section 12 of the Securities Exchange Act of 1934 (Filed With SEC on March 4, 2021)
- Offer Letter, dated as of March 20, 2020, by and between Menlo Therapeutics Inc. and Andrew Saik (Filed With SEC on May 11, 2020)
- Offer Letter, dated as of March 25, 2020, by and between Menlo Therapeutics Inc. and David Domzalski (Filed With SEC on May 11, 2020)
- Description of Securities Registered Under Section 12 of the Securities Exchange Act of 1934 (Filed With SEC on March 3, 2020)
- Form of CSR Agreement (Filed With SEC on November 12, 2019)
- Amendment No. 1 to Offer Letter, by and between the Registrant and Mary Spellman, effective as of April 22, 2018 (Filed With SEC on November 7, 2018)
- Offer Letter, by and between the Registrant and Mary Spellman, effective as of July 21, 2017 (Filed With SEC on November 7, 2018)
- Amendment No. 1 to Offer Letter, by and between the Company and Paul Kwon, effective as of May 3, 2018 (Filed With SEC on May 7, 2018)
- Amendment No. 1 to Offer Letter, by and between the Company and Kristine Ball, effective as of May 3, 2018 (Filed With SEC on May 7, 2018)
- Amendment No. 1 to Offer Letter, by and between the Company and Steven Basta, effective as of May 3, 2018 (Filed With SEC on May 7, 2018)
- Offer Letter, dated as of August 15, 2017 by and between the Company and Kristine Ball (Filed With SEC on December 28, 2017)
- Offer Letter, dated as of January 14, 2016 by and between the Company and Paul Kwon (Filed With SEC on December 28, 2017)
- Offer Letter, dated as of August 17, 2015 by and between the Company and Steven Basta (Filed With SEC on December 28, 2017)